Maintenance Therapy for Severe Atopic Dermatitis in Remission
For a 30-year-old patient with severe atopic dermatitis in remission, continue systemic therapy (dupilumab, tralokinumab, lebrikizumab, nemolizumab, or JAK inhibitors) combined with concomitant topical anti-inflammatory agents for maintenance of remission. 1, 2
Recommended Maintenance Strategy
The most recent AAD guidelines (2025) provide strong recommendations for continuing systemic biologics or JAK inhibitors with concomitant topical therapy for maintenance 1. The 2024 AAD guidelines explicitly state that "topical agents can be used concurrently with phototherapy or systemic agents for maintenance of response, rescue, or treatment of flares" 2.
First-Line Systemic Maintenance Options:
Biologics (Preferred):
- Dupilumab (300 mg subcutaneously every 2 weeks) - All guideline workgroup members favored this as first-line systemic therapy, with excellent safety track record over 5+ years 2
- Tralokinumab (300 mg every 2 weeks after loading) - Strong recommendation, though somewhat less effective than dupilumab 1, 2
- Lebrikizumab - Strong recommendation with concomitant topical therapy; notably, 28% of responders maintained stable EASI 90 response for up to 38 weeks even after discontinuation 1, 3
- Nemolizumab - Strong recommendation with concomitant topical therapy 1
JAK Inhibitors:
- Upadacitinib - Real-world data shows 63.5% maintained remission over 48 weeks; maintaining on-label dosing (15-30 mg daily) showed better outcomes (64.1% remission maintenance) compared to discontinuation (37.5%) 4
- Abrocitinib - Flexible dosing approach allows tailoring to individual disease course; safety profile reflects current dosage with no carry-over risk from previous higher doses 5
- Baricitinib - Strong recommendation 2
Concomitant Topical Therapy:
Do not discontinue topical anti-inflammatory medications once remission is achieved. Continue proactive maintenance with:
- Topical corticosteroids (TCS) applied to previously affected areas
- Topical calcineurin inhibitors (TCI)
- Newer topical agents: Tapinarof cream or roflumilast cream (strong recommendations) 1
Apply twice weekly to areas that were previously affected, even if skin appears clear. This proactive approach treats subclinical inflammation that persists beneath normal-appearing skin 6.
Critical Pitfalls to Avoid:
1. Do NOT discontinue systemic therapy abruptly once remission is achieved. Real-world data demonstrates that discontinuation leads to significantly higher relapse rates (37.5% maintained remission) compared to continuing on-label dosing (64.1% maintained remission) 4.
2. Do NOT stop topical therapy when starting or continuing systemic agents. The guidelines emphasize concurrent use, not sequential replacement 1, 2.
3. Avoid systemic corticosteroids for maintenance - the AAD makes a conditional recommendation AGAINST their use 2.
Dosing Strategy Considerations:
For patients on JAK inhibitors who have achieved sustained remission (≥24 weeks), cautious dose spacing or reduction may be considered, though maintaining on-label dosing shows better outcomes 4. Longer duration of on-label treatment before any tapering attempt is associated with lower relapse risk 4.
For biologics, particularly lebrikizumab, some patients (28%) can maintain deep remission even after discontinuation, though this is not predictable 3.
Application Technique for Topical Maintenance:
Based on real-world practice patterns, apply topical anti-inflammatory agents 7:
- To previously affected areas and surrounding skin (not just visible lesions)
- Using fingertip-unit (FTU) measurements for appropriate amounts
- With adequate thickness (not "thinly" as commonly mispracticed)
The evidence strongly supports that subclinical inflammation persists in normal-appearing skin and requires ongoing treatment 6. Failure to achieve complete initial control increases relapse risk by 31-36% 6.